(secondQuint)Evaluation of Relapse, Efficacy and Safety of Long-term Treatment With Oracea vs Placebo.

 Adult subjects with moderate to severe papulopustular rosacea will receive Oracea(R) and MetroGel(R) 1% once daily during phase 1 (baseline to week 12) of the study.

 Subjects will be eligible to enter phase 2 of the study based upon improvements in the Investigator's Global Assessment (IGA) score.

 During phase 2, subjects will receive either Oracea(R) or placebo once daily for up to an additional 40 weeks.

 Subjects who relapse during phase 2 will be discontinued from the study.

.

 Evaluation of Relapse, Efficacy and Safety of Long-term Treatment With Oracea vs Placebo@highlight

The purpose of this study is to assess relapse, efficacy and safety in subjects with rosacea during long-term treatment with either Oracea(R) or placebo, after an initial 12-week regimen of Oracea(R) and MetroGel(R) 1%.

